Maria Patrizia Stoppelli
Overview
Explore the profile of Maria Patrizia Stoppelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santoro F, Merlino F, Brancaccio D, Camerino I, Belli S, Cimmino A, et al.
Cells
. 2025 Feb;
14(4).
PMID: 39996732
Despite extensive efforts to develop new treatments, the prognosis for glioblastoma multiforme (GBM) is extremely unfavorable, urging the identification of new chemotherapeutics. A previous work identified the cyclic decapeptide uPAcyclin...
2.
Camerino I, Franco P, Bajetto A, Thellung S, Florio T, Stoppelli M, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519339
Glioblastoma (GBM) is the most aggressive type of brain tumor, characterized by poor outcome and limited therapeutic options. During tumor progression, GBM may undergo the process of vasculogenic mimicry (VM),...
3.
Affinito A, Quintavalle C, Chianese R, Roscigno G, Fiore D, DArgenio V, et al.
Cell Death Discov
. 2024 Mar;
10(1):140.
PMID: 38485929
Multiple oncogenic alterations contribute to breast cancer development. Metabolic reprogramming, deeply contributing to tumor microenvironment (TME) education, is now widely recognized as a hallmark of cancer. The reverse Warburg effect...
4.
Franco P, Camerino I, Merlino F, DAngelo M, Cimmino A, Carotenuto A, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835469
Among the deadliest human cancers is glioblastoma (GBM) for which new treatment approaches are urgently needed. Here, the effects of the cyclic decapeptide, uPAcyclin, are investigated using the U87-MG, U251-MG,...
5.
Scognamiglio I, Cocca L, Puoti I, Palma F, Ingenito F, Quintavalle C, et al.
Mol Ther Nucleic Acids
. 2022 Sep;
29:656.
PMID: 36090750
[This corrects the article DOI: 10.1016/j.omtn.2022.02.013.].
6.
Mantile F, Kisovec M, Adamo G, Romancino D, Hocevar M, Bozic D, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954365
Tumor growth and metastasis strongly rely on cell-cell communication. One of the mechanisms by which tumor cells communicate involves the release and uptake of lipid membrane encapsulated particles full of...
7.
Alfano D, Franco P, Stoppelli M
Front Cell Dev Biol
. 2022 May;
10:818616.
PMID: 35493073
Urokinase-type plasminogen activator receptor (uPAR or CD87) is a glycosyl-phosphatidyl-inositol anchored (GPI) membrane protein. The uPAR primary ligand is the serine protease urokinase (uPA), converting plasminogen into plasmin, a broad...
8.
Scognamiglio I, Cocca L, Puoti I, Palma F, Ingenito F, Quintavalle C, et al.
Mol Ther Nucleic Acids
. 2022 Mar;
28:17-31.
PMID: 35317202
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. TNBC progression is sustained by recruitment of a strong tumor microenvironment (TME) mainly composed of cancer-associated fibroblasts (CAFs) able...
9.
Iommelli F, De Rosa V, Terlizzi C, Fonti R, Camerlingo R, Stoppelli M, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33922104
Notch1 plays a key role in epithelial-mesenchymal transition (EMT) and in the maintenance of cancer stem cells. In the present study we tested whether high levels of activated Notch1 in...
10.
Belli S, Franco P, Iommelli F, De Vincenzo A, Brancaccio D, Telesca M, et al.
Cancers (Basel)
. 2020 Aug;
12(9).
PMID: 32847144
Among peritumoral cells, cancer-associated fibroblasts (CAFs) are major facilitators of tumor progression. This study describes the effects of two urokinase-derived, novel decapeptides, denoted as Pep 1 and its cyclic derivative...